keyword
MENU ▼
Read by QxMD icon Read
search

Fampridine

keyword
https://www.readbyqxmd.com/read/28992626/multiple-sclerosis-and-clinical-gait-analysis-before-and-after-fampridine-a-systematic-review
#1
Magaly Lecat, Pierre Decavel, Eloi Magnin, Brigitte Lucas, Vincent Gremeaux, Yoshimasa Sagawa
BACKGROUND: Gait impairment is one of the most disabling symptoms in people with multiple sclerosis (PwMS). Fampridine, has demonstrated a positive effect on gait speed in PwMS after 14 days of treatment but the long-term effects have not yet been demonstrated. This study reviews the long-term effects of fampridine on gait in PwMS. SUMMARY: This systematic review was conducted according to the PRISMA statement. Studies were considered long term if treatment exceeded 28 days...
October 9, 2017: European Neurology
https://www.readbyqxmd.com/read/28987349/corrigendum-to-high-throughput-liquid-chromatography-tandem-mass-spectrometry-method-for-simultaneous-determination-of-fampridine-paroxetine-and-quinidine-in-rat-plasma-application-to-in%C3%A2-vivo-perfusion-study-j-food-drug-anal-24-2016-866-875
#2
https://www.readbyqxmd.com/read/28911626/high-throughput-liquid-chromatography-tandem-mass-spectrometry-method-for-simultaneous-determination-of-fampridine-paroxetine-and-quinidine-in-rat-plasma-application-to-in%C3%A2-vivo-perfusion-study
#3
Suneetha Achanti, Raja Rajeswari Katta
A selective and high-throughput liquid chromatography-mass spectrometry method has been developed and validated for the simultaneous quantification of paroxetine, fampridine, and quinidine in rat plasma using imipramine as an internal standard. Following protein precipitation extraction, the analytes and internal standard were run on XBridge C18 column (150 mm × 4.6 mm, 5 μm) using a gradient mobile phase consisting of 5mM ammonium formate in water (pH 9.0) and acetonitrile in a flow gradience program...
October 2016: Journal of Food and Drug Analysis
https://www.readbyqxmd.com/read/28894033/author-response-monitoring-long-term-efficacy-of-fampridine-in-gait-impaired-patients-with-multiple-sclerosis
#4
Linard Filli, Björn Zörner, Tim Killeen, Michael Linnebank
No abstract text is available yet for this article.
September 12, 2017: Neurology
https://www.readbyqxmd.com/read/28894032/letter-re-monitoring-long-term-efficacy-of-fampridine-in-gait-impaired-patients-with-multiple-sclerosis
#5
Floyd A Davis
No abstract text is available yet for this article.
September 12, 2017: Neurology
https://www.readbyqxmd.com/read/28864863/fampridine-prolonged-release-a-review-in-multiple-sclerosis-patients-with-walking-disability
#6
Esther S Kim
Oral fampridine prolonged release (PR) [Fampyra®] is a lipid-soluble selective potassium channel blocker that is approved in the EU for the improvement of walking in adult multiple sclerosis (MS) patients with walking disability (expanded disability status scale score of 4-7). In clinical trials (MS-F203 and MS-F204) using an objective measure of walking improvement [the timed 25-foot walk (T25FW)], more than one-third of patients receiving fampridine PR achieved a consistent on-treatment improvement in walking speed (i...
September 2017: Drugs
https://www.readbyqxmd.com/read/28741976/fampridine-response-in-ms-patients-with-gait-impairment-in-a-real-world-setting-need-for-new-response-criteria
#7
Francisco Alejandro Rodriguez-Leal, Rocco Haase, Katja Thomas, Judith Christina Eisele, Undine Proschmann, Thorsten Schultheiss, Raimar Kern, Tjalf Ziemssen
OBJECTIVE: The primary objective of this real-world study was to describe the response to fampridine and changes of gait parameters in multiple sclerosis (MS) patients' walking disability (Expanded Disability Status Scale (EDSS): 4-7) after treatment with fampridine for 2 weeks as recommended by the European Medicines Agency (EMA) and compare it with the overall physician's judgement. METHODS: A total of 211 adult MS patients were analyzed using a multimodal gait assessment including the timed 25-foot walk test (T25FW), 2-minute walking test (2-MWT), 12-item Multiple Sclerosis Walking Scale (MSWS-12), the GAITRite electronic walkway system, and the patients' clinical global impression (CGI)...
July 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28397001/gait-ataxia-in-humans-vestibular-and-cerebellar-control-of-dynamic-stability
#8
Roman Schniepp, Ken Möhwald, Max Wuehr
During human locomotion, vestibular feedback control is fundamental for maintaining dynamic stability and adapting the gait pattern to external circumstances. Within the supraspinal locomotor network, the cerebellum represents the key site for the integration of vestibular feedback information. The cerebellum is further important for the fine-tuning and coordination of limb movements during walking. The aim of this review article is to highlight the shared structural and functional sensorimotor principles in vestibular and cerebellar locomotion control...
October 2017: Journal of Neurology
https://www.readbyqxmd.com/read/28376639/the-effect-of-symptom-controlling-medication-on-gait-outcomes-in-people-with-multiple-sclerosis-a-systematic-review
#9
Kate Behm, Prue Morgan
PURPOSE: To synthesise and critically appraise randomised controlled trials examining the effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis (MS). METHOD: The literature search examined five databases (Medline, Embase, AMED, Cochrane (CENTRAL), and CINAHL until the end of November 2016. Eligible studies included medication to address symptoms associated with MS and an objective gait outcome measure. Two reviewers independently extracted data and assessed study quality using structured data extraction forms and the PEDro scale...
April 4, 2017: Disability and Rehabilitation
https://www.readbyqxmd.com/read/28347283/healthcare-resource-use-and-costs-of-multiple-sclerosis-patients-in-germany-before-and-during-fampridine-treatment
#10
Tjalf Ziemssen, Christine Prosser, Jennifer Scarlet Haas, Andrew Lee, Sebastian Braun, Pamela Landsman-Blumberg, Angela Kempel, Erika Gleißner, Sarita Patel, Ming-Yi Huang
BACKGROUND: Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS patients on fampridine treatment for 12 months in Germany were analyzed. METHODS: A retrospective claims database analysis was conducted including MS patients who initiated fampridine treatment (index date) between July 2011 and December 2013...
March 27, 2017: BMC Neurology
https://www.readbyqxmd.com/read/28236802/assessment-of-the-efficacy-and-safety-of-fampridine
#11
Beatriz Mejuto, Paloma Castellano, Concepción Castro, Luis Manuel López
OBJECTIVE: Assessment of the efficacy and safety of fampridine for walking improvement in adult patients with multiple sclerosis. METHOD: A descriptive retrospective study of all patients who initiated treatment with fampridine between March, 2014 and February, 2015. Efficacy was assessed through the 25-foot walk test and the 12-item walking scale for multiple sclerosis. It was reviewed whether patients had suffered any of the most frequent adverse effects described in the pivotal clinical trial...
March 1, 2017: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/28148629/monitoring-long-term-efficacy-of-fampridine-in-gait-impaired-patients-with-multiple-sclerosis
#12
RANDOMIZED CONTROLLED TRIAL
Linard Filli, Björn Zörner, Sandra Kapitza, Katja Reuter, Lilla Lörincz, David Weller, Tabea Sutter, Tim Killeen, Philipp Gruber, Jens A Petersen, Michael Weller, Michael Linnebank
OBJECTIVE: To expand upon the limited knowledge of the long-term effects of prolonged-release (PR) fampridine in patients with multiple sclerosis (PwMS) regarding safety, walking improvements, and changes in drug responsiveness. METHODS: Fifty-three PwMS who completed the FAMPKIN core study were included in this extension trial. Drug efficacy was assessed in an open-label and randomized double-blind, placebo-controlled study design with regular baseline assessments over a period of 2 years using the Timed 25-Foot Walk (T25FW), 6-Minute Walk Test (6MWT), and 12-item MS Walking Scale (MSWS-12) as outcome measures...
February 28, 2017: Neurology
https://www.readbyqxmd.com/read/28148627/fampridine-long-term-benefits-in-walking-in-multiple-sclerosis
#13
EDITORIAL
Susan E Bennett
No abstract text is available yet for this article.
February 28, 2017: Neurology
https://www.readbyqxmd.com/read/28104253/the-effect-of-fampridine-sr-on-cognitive-fatigue-in-a-randomized-double-blind-crossover-trial-in-patients-with-ms
#14
RANDOMIZED CONTROLLED TRIAL
Sarah A Morrow, Heather Rosehart, Andrew M Johnson
BACKGROUND: Cognitive fatigue (CF) is a common complaint in persons with MS (PwMS). Fampridine-SR improves ambulation, fatigue and endurance, due to enhancing action potential formation by blocking potassium channels in demyelinated axons. Thus, through this same mechanism, it is hypothesized that Fampridine-SR could improve CF. OBJECTIVE: To determine if Fampridine-SR objectively improves CF in PwMS. METHODS: Sixty PwMS of any type with CF, defined as 3 or less correct responses when comparing the last third to the first third on the Paced Auditory Serial Addition Test (PASAT), were recruited from a tertiary care MS clinic in London (ON) Canada...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28054826/experience-with-fampridine-in-clinical-practice-analysis-of-a-possible-marker-of-clinical-response
#15
Miriam Alvarez-Payero, Candelas Valeiras-Muñoz, Susana Lion-Vázquez, Guadalupe Piñeiro-Corrales, Delicias Muñoz-García, Luciana Midaglia
PURPOSE OF THE STUDY: Approximately 85% of patients with multiple sclerosis experience reduced mobility, which negatively affects quality of life. Fampridine is the first symptomatic treatment aimed at improving gait. We analyzed effectiveness and tolerance in clinical practice. We also sought a prevalent gait pattern in responders as a potential clinical response marker. MATERIAL AND METHODS: Six-month prospective study of fampridine in patients with multiple sclerosis...
March 30, 2017: International Journal of Neuroscience
https://www.readbyqxmd.com/read/27919481/effect-of-slow-release-fampridine-on-muscle-strength-rate-of-force-development-functional-capacity-and-cognitive-function-in-an-enriched-population-of-ms-patients-a-randomized-double-blind-placebo-controlled-study
#16
RANDOMIZED CONTROLLED TRIAL
H B Jensen, J L Nielsen, M Ravnborg, U Dalgas, P Aagaard, E Stenager
DESIGN: This study was conducted as a randomized, double blind, placebo-controlled parallel group trial preceded by open label enrichment phase. OBJECTIVES: The objectives of this study were 1) to examine the effect of SR-Fampridine treatment on muscle strength in terms of maximal voluntary contraction (MVC) and rate of force development (RFD) of the lower extremities and 2) to replicate previously published data on the effect of slow release-Fampridine (SR-Fampridine) on the functional capacity of the lower limbs, the upper limb and cognitive function, in persons with multiple sclerosis (pwMS)...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27904656/the-berlin-treatment-algorithm-recommendations-for-tailored-innovative-therapeutic-strategies-for-multiple-sclerosis-related-fatigue
#17
REVIEW
Christian Veauthier, Helge Hasselmann, Stefan M Gold, Friedemann Paul
More than 80% of multiple sclerosis (MS) patients suffer from fatigue. Despite this, there are few therapeutic options and evidence-based pharmacological treatments are lacking. The associated societal burden is substantial (MS fatigue is a major reason for part-time employment or early retirement), and at least one out of four MS patients view fatigue as the most burdensome symptom of their disease. The mechanisms underlying MS-related fatigue are poorly understood, and objective criteria for distinguishing and evaluating levels of fatigue and tiredness have not yet been developed...
2016: EPMA Journal
https://www.readbyqxmd.com/read/27871056/fampridine-treatment-and-walking-distance-in-multiple-sclerosis-a-randomised-controlled-trial
#18
RANDOMIZED CONTROLLED TRIAL
Hannah Pickering, Jenna Murray, Cindy S-Y Lin, Christine Cormack, Andrew Martin, Matthew C Kiernan, Arun V Krishnan
OBJECTIVE: To explore the benefits of modified-release fampridine on walking distance in MS. METHODS: This was a randomised double-blind, placebo-controlled crossover trial of fampridine in 25 MS patients. The primary outcome measure was the six minute walk test (6MWT). A p-value<10% led to rejection of the null hypothesis. RESULTS: The pre-specified criterion for statistical significance was met, with a 17m improvement in 6MWT in the treatment arm...
January 2017: Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology
https://www.readbyqxmd.com/read/27772740/prolonged-release-fampridine-treatment-improved-subject-reported-impact-of-multiple-sclerosis-item-level-analysis-of-the-msis-29
#19
RANDOMIZED CONTROLLED TRIAL
Claudio Gasperini, Raymond Hupperts, Jan Lycke, Christine Short, Manjit McNeill, John Zhong, Lahar R Mehta
Prolonged-release (PR) fampridine is approved to treat walking impairment in persons with multiple sclerosis (MS); however, treatment benefits may extend beyond walking. MOBILE was a phase 2, 24-week, double-blind, placebo-controlled exploratory study to assess the impact of 10mg PR-fampridine twice daily versus placebo on several subject-assessed measures. This analysis evaluated the physical and psychological health outcomes of subjects with progressing or relapsing MS from individual items of the Multiple Sclerosis Impact Scale (MSIS-29)...
November 15, 2016: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/27676913/-gait-responder-to-fampridine-a-too-restrictive-concept
#20
Mehri Christopher, Yoshimasa Sagawa, Céline Bernard, Thierry Moulin, Eloi Magnin, Pierre Decavel
OBJECTIVE: Fampridine is used as a symptomatic treatment in patients with multiple sclerosis (PwMS) gait disorders. Some clinical trials reported a positive effect on cognitive function especially on information-processing speed (IPS) or on fatigue. The aim of our clinical trial was to evaluate the effect of fampridine on IPS. MATERIAL/PATIENTS AND METHODS: 60 PwMS with an EDSS score between 4 and 7 were included in a prospective monocentric open label trial. Two identical measures were conducted a week apart before initiating treatment in order to take into account the test-retest effect...
September 2016: Annals of Physical and Rehabilitation Medicine
keyword
keyword
44475
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"